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Background: Acylcarnitine (AC) transport dysfunction into the mitochondrial matrix is one of the
pathophysiological mechanisms of type 2 diabetes mellitus (DM). The effect of an aerobic exercise (AE) program on
this condition in obese subjects without DM is unclear.
Methods: A prospective, randomized, longitudinal, interventional study in a University Research Center involved a
10-week AE program in 32 women without DM and a body mass index (BMI) greater than 27 kg/m2. (Cases n = 17;
Controls n = 15). The primary objective was to evaluate the influence of a controlled AE program on beta-oxidation
according to modifications in short, medium, and long-chain ACs. Secondary objectives were to define the
behavior of amino acids, and the correlation between these modifications with metabolic and
anthropometric markers.
Results: The proportion of dropouts was 17% and 6% in controls and cases, respectively. In cases there was a
significant reduction in total carnitine (30.40 [95% CI 28.2 to 35.6]) vs. (29.4 [CI 95% 25.1 to 31.7]) p= 0.0008 and long-
chain AC C14 (0.06 [95% CI 0.05 to 0.08]) vs. (0.05 [95% CI 0.05 to 0.09]) p= 0.005 and in C18 (0.31 [95% CI 0.27 to 0.45])
vs. (0.28 [95% CI 0.22 to 0.32]) p= 0.03. Free fatty acid levels remained without change during the study in both groups.
Conclusion: In conclusion, a controlled 10-week AE program improved beta-oxidation by reducing long-chain ACs.
This finding highlights the importance that AE might have in avoiding or reverting lipotoxicity, and in consequence,
improving insulin sensitivity and pancreatic beta cell functional reserve.
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Diabetes Mellitus (DM) and obesity represent an annual
cost of $132 and $147 billion dollars, respectively, for the
United States Healthcare System [1-3]. Their incidence
and severity have increased since the 1970s and it is esti-
mated that by 2050 one third of the population in the Uni-
ted States will suffer from DM and half will be overweight
or obese [4,5]. In Mexico, the problem is no less impres-
sive since from 1988 to 2006 the prevalence of overweight* Correspondence: drfernandolavalle@hotmail.com
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distribution, and reproduction in any mediumand obesity went from 35% to 70% and the prevalence of
DM in 2006 was almost 15% [6,7]. Obesity is one of the
risk factors with the greatest impact on the development
of DM and insulin resistance. The latter abnormality to-
gether with pancreatic beta cell dysfunction represent the
initial pathophysiologic basis of type 2 DM [8,9]. Other
important mechanisms have recently been identified, such
as entero-insular axis dysfunction, increase in glucagon se-
cretion, impaired renal reabsorption of glucose, brain insu-
lin resistance, and lipotoxicity [10-16].
Impairment in long-chain acylcarnitine (AC) transfer to
the mitochondrial matrix that results from dysfunction of
carnitine palmitoyltransferase-1 (CPT1), leads to the accu-
mulation of AC in cells [17,18]. This abnormality is one of
the causes of lipotoxicity, which has been implicated as
one of the mechanisms responsible for insulin resistance
in liver and muscle, and of pancreatic beta cell dysfunctionMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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function is inherited or acquired and whether or not it is
reversible. Recently, Mihalik et al. (2010), using tandem
mass spectrometry in 10 type 2 DM and 14 obese patients,
demonstrated the accumulation of plasmatic long-chain
AC in the mitochondria and its relationship to insulin re-
sistance after an overnight fast and four hours on an
euglycemic clamp [22]. Studies with thiazolidinediones, on
the other hand, have shown that these consequences of
lipotoxicity can be prevented or reversed in subjects with
type 2 DM [23,24]. Hiatt et al. (1989) demonstrated that a
change occurred in the patterns of AC when they evalu-
ated the influence of an episode of aerobic exercise (AE) of
variable intensity in six healthy volunteers [25]. However,
it is unknown whether this effect on the pattern of AC in
a single episode of AE can be repeated or modified when
carrying out a long term AE program. The influence of an
AE program on the pattern of AC has not been studied in
non-diabetic overweight or obese individuals. The identifi-
cation of favorable changes in the ACs pattern of these
populations, when subjected to an AE program, could be
useful to modify the consequences of lipotoxicity.
We designed a randomized, prospective, longitudinal,
experimental study in a group of obese or overweight indi-
viduals who underwent a 10-week AE program. Our main
purpose was to define the influence of an AE program on
beta-oxidation and fatty acid transport in mitochondria
according to changes in total carnitine and short, medium,
and long-chain ACs. We were also interested in studying
the behavior of essential and nonessential amino acids,
and analyzing the correlation of these changes with the
determination of metabolic and anthropometric markers
that can be modified with a controlled AE program.
Subjects and methods
Subjects
After obtaining approval from the Research and Ethics
Committee and informed consent from each subject, we
began the study. Participants were recruited through
advertisements placed in different parts of the health
campus of the Universidad Autónoma de Nuevo León. A
total of 36 women, aged 18 to 24 years with a body mass
index (BMI) greater than or equal to 27 kg/m2 were
included. We excluded individuals who had exercised
periodically in the last 3 months, subjects who had a
weight change greater than 10% in the last 6 months or
who were taking medications that alter insulin sensitivity,
or lipid lowering or antihypertensive drugs during this
period. We also excluded individuals with DM, hyperten-
sion, dyslipidemia or who smoked in the last 6 months.
Study protocol
The participants were consecutively and randomly
assigned to one of two groups: cases and controls. Inorder to prevent a change in calorie intake that would
lead to a modification in body weight, which in turn
would indirectly affect the effects of exercise, all partici-
pants received individual and group nutrition education.
Before starting the AE program, all participants were
measured for anthropometric indexes, such as weight,
height, BMI, waist, hips, percentage of body fat and lean
mass. Also, after a 12 hours overnight fast, blood sam-
ples were drawn for determination of AC, free fatty
acids, amino acids, glucose, insulin, total cholesterol, tri-
glycerides, low-density lipoprotein (LDL), high-density
lipoprotein (HDL), leptin, adiponectin and tumor necro-
sis factor alpha (TNF alpha). These anthropometric mea-
sures and laboratory studies were performed at the
beginning and at the end of the AE program.
The duration of the controlled AE program in both
groups was 10 weeks. The control group received a
manual with a gradual and progressive dose of exercise,
based on recommendations of the American College of
Sports Medicine, using the Borg scale for the perception
of exercise intensity [26,27]. Exercise was performed as
the subject wished; it was not controlled or supervised.
The case group, on the other hand, received a controlled
and supervised AE intervention during the same time
period, with a frequency of five times a week and a dur-
ation of 20 minutes in the first two weeks, reaching 40
minutes by the fourth week; half of the session consisted
of jogging on a treadmill and the other half of ergo-
nomic bike pedaling. During the first three weeks the in-
tensity was 40%-50% of the heart rate reserve (HRR),
then, from the fourth to sixth weeks, the HRR was 50%-
60%. The last 4 weeks were at a HRR of 60% to 80%.
Measures
To perform exercise TRUE Z8 Soft-System treadmills and
TRUE Z8 ergonomic bikes (TRUE Fitness Technology,
Inc. St. Louis, MO) were used. The HRR was monitored
with an Ekho Model E-15 heart rate monitor (Ekho Brand
Americas, LLC, Minneapolis, MN). Calculation of the
HRR to the percentage of desired intensity was performed
in a personalized manner according to the Karvonen
method (ACSM, 2010), using the following formula:
HRR= ([maximum heart rate - resting heart rate] x
desired percentage) + resting heart rate (26). AC and
amino acids were analyzed in an API 2000 Triple Quadru-
pole Mass Spectrometer (PerkinElmer, Waltham, MA)
coupled to a series 200 micropump and autosampler (Per-
kinElmer) using a Neogram kit for AC and amino acid
spectrometry in tandem (PerkinElmer). Waist-hip circum-
ference (WHC) and BMI measurements were performed
according to recommendations of the National Institutes
of Health [28]. BMI was calculated with the following for-
mula: BMI= (weight in kg)/(height in m²). Weight and
height were determined on a Seca 700 calibrated
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icos, Mexico City, Mexico). Anthropometric measure-
ments were performed by an ISAK (International Society
for the Advance of Kinanthropometry) certified individual
who was blinded to participant´s information.
The percentage of body fat and lean body mass were
determined using air displacement plethysmography (Bod-
Pod, Life Measurement, Inc., Concord, CA). The XY
multiplex platform (LuminexW, Luminex Corporation
Austin, TX) with calibration microspheres was used with
MagPlex software that reads magnetic strips for reporting
plasma concentrations of adiponectin, TNFα and leptin.
Plasma glucose measurement was performed using the
glucose oxidase method (Adiva 1650 Chemistry system,
Bayer, Leverkueusen, Germany; intraassay CV <2%); insu-
lin was measured using an immunoassay electrochemilu-
minescence kit (Roche Diagnostics Indianapolis, IN;
intraassay CV <2%), lipid profile was determined with an
Immulite 2000 analyzer (Diagnostic Products Corpor-
ation, Los Angeles, CA; CV <8% for all measurements).
HOMA-IR was calculated using the following formula:
HOMA-IR= fasting serum insulin (uU/ml) x fasting
plasma glucose (mmol/ml)/22.5 [29]. A HOMA less than
or equal to 2.5 was considered the normal cutoff value be-
cause a higher value has been associated with increased
cardiovascular risk in Mexican-American population [30].
Statistical analysis
All results are presented as medians and 95% confidence
intervals (CI), unless otherwise stated. Differences were
considered statistically significant if P was equal or less
than 0.05. To evaluate the anthropometric variables of age
and height we used Student´s t test. For the rest of the an-
thropometric, biochemical, AC and amino acid variables
nonparametric tests were used: the Mann–Whitney U for
comparison of different groups and the Wilcoxon rank
test for comparison of values within a group. Sample size
was calculated based on a change in adiponectin through
the AE intervention, with a power of 80%, an effect size of
38% and a significance level of 0.05. This resulted in an n
per group of 16 subjects. Statistical analysis was per-
formed with SPSS Statistics 15.0 (SPSS Inc., Armonk, NY)
and with MedCalc Version 11.4.4.0 for Windows (Med-
Calc Software, Ghent, Belgium).
Results
Study population
Eighteen participants were randomized into each group.
In the control group 15 out of 18 participants (83%)
completed the study period, in contrast to 17 out of 18
(94%) in the case group. The four participants who
dropped out of the study did so within the first 2 weeks.
In the control group 13 out of 15 participants attended
at least 3 of the 5 uncontrolled weekly workout sessionsthroughout the study, whereas in the case group, of
the 17 participants, 100% attended at least 4 weekly
controlled AE sessions and 14 attended all sessions.
The mean age of the case group and controls was
20.3 years ± 1.44 SD and 21.5 years ± 2.19 SD, respect-
ively (p = 0.08).
Anthropometric and metabolic variables
A: Baseline characteristics
The baseline anthropometric and metabolic characteris-
tics of each group are shown in Table 1. Initially there
were 8 vs. 9 participants overweight in the case group
and controls, respectively. There were 9 vs. 6 cases and
controls, respectively, with obesity (p= 0.23). There was
also no statistically significant differences between case
and control groups when the median of all anthropo-
metric measures including weight, height, BMI, percent
body fat, lean body mass, waist, hips and waist/hip ratio
were evaluated. Although the median weight in the
group of cases vs. controls was higher (81.10 kg [95% CI
72.08 to 84.70]) vs. (72.20 kg [95% CI 66.55 to 80.75])
p= 0.06, this was not significant. This discrepancy was
attenuated when BMI was compared between the groups
of cases and controls (30.50 kg/m2 [95% CI 28.50 to
32.69]) vs. (28.89 kg/m2 [95% CI 27.78 to 31.12]) p = 0.15,
respectively. The metabolic variables were not statisti-
cally different in levels of adiponectin, leptin, insulin,
TNF alpha, total cholesterol, triglycerides, HDL, LDL,
and levels of free fatty acids. There was only a significant
difference in median fasting glucose, 74 mg/dl (95% CI
73 to 78.96) in the case group vs. 84 mg/dl (80.26 to
88.0) in the control group (p = 0.003); while the median
HOMA was 2.2 (95% CI 1.6 to 3.0) vs. 2.9 (CI 95% 2.3 to
5.2) for cases and controls, respectively (p = 0.047).
B: Comparison of baseline vs. End of the study in each
group
In the control group there was no statistically significant
difference in the anthropometric characteristics when
compared before vs. after 10 weeks of the AE program
(Table 1). However, in the case group after 10 weeks of
an AE program a favorable change in all variables oc-
curred, reaching statistical significance. It is noteworthy
that in this group there was a decrease in the median
weight of about 5 kg, 81.10 kg. (95% CI 72.08 to 84.69)
vs. 76.30 kg (95% CI 69.90 to 82.22).
When baseline metabolic vs. endpoint variables were
compared in the control group, insulin was the only vari-
able with a statistically significant reduction, 13.72 uUI/ml
(95% CI 11.47 to 24.95) vs. 12.73 uUI/ml (95% CI 10.70 to
19.43), p= 0.01. On the other hand, expected significant
changes occurred in cases in leptin, adiponectin, and low-
density lipoprotein levels. The mean plasma glucose,
increased in a significant level, 74 mg/dl [95% CI (73.0 to
Table 1 Baseline and End of Study Anthropometric and Metabolic Measures in Controls and Cases
Baseline P+ End of the Study P+ A vs. C{ B vs. D{
Control (A) n = 15 Case (B) n = 17 Control (C) n = 15 Case (D) n = 17
Age, y } 21.5 ± 2.19 20.3 ± 1.44 0.08 72.40 (65.66 – 82.08) 76.30 (69.90 – 82.22) 0.39 0.80 0.0003*
Weight, kg. 72.20 (66.55 – 80.75) 81.10 (72.08–84.7) 0.06
Height, cm 157 (151.26 – 163.47) 161 (156 - 164) 0.24
BMI kg/m2 28.89 (27.78 – 31.12) 30.50 (28.50 – 32. 69) 0.15 29.10 (27.73. 30.88) 28.80 (27.50 – 30.78) 0.74 0.76 0.0002*
FM kg 26.7 (23.15 – 31.26) 32.6 (23.51 – 34.4) 0.08 27.60 (23.50 – 31.01) 29.40 (23.12 – 33.07) 0.67 0.58 0.0005*
FFM kg 45.70 (42.13 – 48.26) 48.70 (46.20 – 50.29) 0.08 44.80 (41.75 – 47.94) 47.90 (45.80 – 49.39) 0.06 0.13 0.03*
Waist cm 83 (80.38 – 88) 86.40 (82.02 – 91.98) 0.24 82.50 (79.76 – 86.15) 83 (79.50 – 86) 0.74 0.11 < 0.0001*
Hip cm 108 (102.26 – 110.62) 112.5 (105.04 – 115.46) 0.07 106.5 (102.52 – 108.73) 108 (103 – 111) 0.76 0.54 0.0002*
Waist to Hip Ratio 0.79 (0.76 - 0.81) 0.78 (0.77 - 0.81) 0.80 0.77 (0.75 - 0.80) 0.78 (0.75 - 0.79) 0.63 0.27 0.04*
Adiponectin ug/ml 11.54 (7.88 – 15.26) 11.72 (7.29 – 15.06) 0.61 12.33 (8.36 – 15.60) 15.76 (9.96 – 23.44) 0.32 0.80 < 0.0001*
Leptin ng/ml 30.33 (25.30 – 36.06) 28.31 (23.82 – 35.12) 0.71 29.42 (21.51 – 37) 18.13 (12.94 – 24.31) 0.002* 0.45 0.03*
TNFa pg/ml 4.44 (4.10 – 6.14) 4.33 (2.90 – 5.31) 0.25 5.05 (4.12 – 6.76) 4.10 (3.53 – 4.98) 0.036* 0.12 0.93
Insulin, mg/dl 13.72 (11.47 – 24.95) 12.01 (8.64–16.74) 0.14 12.73 (10.70 – 19.43) 12.89 (6.42 – 14.37) 0.12 0.01* 0.17
Glucose, mg/dl 84 (80.26 – 88) 74 (73–78.96) 0.003* 86 (82.26 – 87) 82 (76.01 – 87) 0.39 0.80 0.05*
CHOL, mg/dl 78 (59.05 – 149.02) 78 (62.03 – 111.79) 0.69 78 (65.79 – 113) 66 (59.03 – 99-95) 0.15 0.59 0.33
TGL mg/dl 160 (144.52 – 182.41) 153 (144.04 – 186.98) 0.87 165 (149.70 – 186.73) 168 (152.01 – 184. 91) 0.79 0.42 0.12
HDL mg/dl 49 (36.26 – 54.94) 45 (41.01 – 71.74) 0.39 45 (39.26 – 53.47) 44 (40 – 55.93) 0.98 0.84 0.32
LDL mg/dl 104 (98–109.47) 105 (102.01 – 109.98) 0.50 95 (90 – 102.41) 92 (80.12 – 97.98) 0.36 0.20 0.0001*
HOMA 2.88 (2.29 – 5.20) 2.22 (1.59 – 3.01) 0.047* 2.58 (2.29 – 4.20) 2.29 (1.47 – 2.83) 0.15 0.06 0.40
FFA mEq/L 0.40 (0.30 - 0.50) 0.40 (0.30 - 0.59) 0.39 0.50 (0.32 - 0.60) 0.40 (0.40 - 0.60) 0.86 0.27 0.23
^ Results are reported in median and 95% Confidence Interval, except age (}), which is mean ± SD.
FFA denotes Free-fat Mass, FM fat mass, BMI body mass index, W/H Waist to Hip Ratio, TNFa tumor necrosis factor alpha, CHOL Cholesterol, TGL Triglycerides, HOMA Homeostatic Model Assessment, HDL high-density
lipoprotein, LDL low-density lipoprotein, FFA Free fatty acids.
+p Values where calculated by Mann–Whitney Test.
{p Values where calculated by Wilcoxon Rank Test.
* Significant Result p < 0.05.
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in this group plasma insulin levels remained unchanged.
C: Comparison between groups at the end of the study
After 10 weeks of AE, when contrasting the anthropomet-
ric variables among the groups there was no significant
difference in any of the studied variables (Table 1). How-
ever, when the metabolic variables were compared, signifi-
cantly lower values in the case group in leptin and TNF
alpha were found.
Acylcarnitines
At baseline, a difference in short-chain AC levels (C3DC
and C4) between cases and controls was found; these
were significantly higher in the control group (SeeTable 2 Baseline and End of Study Acylcarnitines in Controls
Baseline p+
Control (A) n = 15 Case (B) n = 17 Con
C0 30.20 (24.80–34.31) 30.40 (28.21–35.58) 0.42 30.1
C2 8.23 (6.02–9.94) 7.21 (5.61–11.98) 0.94 6.7
C3 0.65 (0.54–0.82) 0.61 (0.49–0.74) 0.60 0.7
C3DC 0.08 (0.07–0.10) 0.06 (0.04–0.08) 0.01* 0.0
C4 0.19 (0.14–0.20) 0.11 (0.07–0.16) 0.02* 0.1
C4DC 0.41 (0.25–0.56) 0.45 (0.33–0.53) 0.68 0.4
C5 0.14 (0.12–0.18) 0.12 (0.10–0.15) 0.77 0.1
C5OH 0.20 (0.13–0.29) 0.25 (0.18–0.28) 0.48 0.2
C5:1 0.03 (0.02–0.4) 0.03 (0.02–0.5) 0.89 0.0
C5DC 0.09 (0.04–0.19) 0.09 (0.05–0.12) 0.40 0.0
C6 0.07 (0.04–0.09) 0.05 (0.04–0.08) 0.79 0.0
C6DC 0.07 (0.04–0.10) 0.06 (0.05–0.08) 0.25 0.0
C8 0.11 (0.07–0.14) 0.06 (0.04–0.07) 0.006* 0.0
C10 0.07 (0.05–0.10) 0.07 (0.04–0.12) 0.71 0.0
C10:1 0.09 (0.06–0.13) 0.08 (0.05–0.10) 0.34 0.0
C10:2 0.06 (0.01–0.10) 0.05 (0.02–0.09) 0.74 0.0
C12 0.07 (0.04–0.11) 0.07 (0.05–0.09) 0.66 0.0
C14 0.06 (0.04–0.09) 0.06 (0.05–0.08) 0.69 0.0
C14:1 0.07 (0.02–0.10) 0.06 (0.05–0.08) 0.55 0.0
C14:2 0.03 (0.03–0.06) 0.04 (0.02–0.07) 0.49 0.0
C16 0.67 (0.52–0.67) 0.60 (0.50–0.73) 0.47 0.5
C160H 0.04 (0.02–0.05) 0.03 (0.03–0.05) 0.58 0.0
C16:1 0.07 (0.06–0.10) 0.06 (0.03–0.08) 0.10 0.0
C16:1 OH 0.08 (0.06–0.09) 0.09 (0.07–0.11) 0.26 0.0
C18 0.37 (0.32–0.41) 0.31 (0.27–0.45) 0.24 0.3
C18 OH 0.06 (0.03–0.10) 0.04 (0.03–0.08) 0.66 0.0
C18:1 0.64 (0.59–0.81) 0.74 (0.68–0.84) 0.13 0.6
C18:1 OH 0.03 (0.02–0.03) 0.02 (0.02–0.03) 0.42 0.0
C18:2 0.22 (0.18–0.33) 0.28 (0.22–0.32) 0.36 0.2
^All values are in μmol/l. Results are reported in Median and Confidence Interval 9
+p Values were calculated by Mann–Whitney Test.
{p Values were calculated by Wilcoxon Rank Test.
* Significant Result p < 0.05.Table 2). Also, the levels of a single medium-chain AC,
C8, were significantly higher in controls. There were no
differences between long-chain AC groups. At the end
of the exercise program in the control group, a compari-
son of baseline vs. end AC levels showed a significant in-
crease in short-chain AC C3 (0.65 [95% CI 0.54 to 0.82]
vs. 0.77 [95% CI 0.64 to 0.93]) and long-chain AC
C16OH (0.04 [95% CI 0.02 to 0.05] vs. 0.07 [0.04 to
0.09]). In the case group there was a significant decrease
in total carnitine (30.40 [95% CI 28.21to 35.58] vs. 29.40
[95% CI 25.12 to 31.69]) and long-chain AC C14 (0.09
[95% CI 0.05 to 0.12] vs. 0.05 [95% CI 0.04 to 0.09]) and
AC C18 (0.31 [95% CI 0.27-0.45] vs. 0.28 [95% CI 0.22
to 0.32]). In this group there was a significant increase
in medium-chain AC C8 (0.06 [95% CI 0.04 to 0.07] vs.and Cases
End of the Study p+ A vs C{ B vs D{
trol (C) n = 15 Case (D) n = 17
0 (24.23–34.74) 29.40 (25.12–31.69) 0.61 0.20 0.0008*
8 (5.77–9.79) 6.89 (5.47–10.29) 0.95 0.22 0.24
7 (0.64–0.93) 0.68 (0.50–0.84) 0.18 0.006* 0.35
8 (0.05–0.09) 0.06 (0.04–0.11) 0.89 0.38 0.32
8 (0.12–0.24) 0.13 (0.10–0.16) 0.10 0.27 0.48
1 (0.30–0.53) 0.50 (0.33–0.54) 0.71 0.27 0.74
6 (0.14–0.20) 0.19 (0.15–0.24) 0.06 0.63 0.050*
2 (0.14–0.24) 0.24 (0.18–0.27) 0.29 0.59 0.96
3 (0.02–0.06) 0.03 (0.02–0.05) 1.00 0.90 0.78
8(0.06–0.10) 0.08 (0.06–0.10) 0.18 0.48 0.14
4 (0.03–0.08) 0.05 (0.03–0.07) 0.74 0.20 0.82
6 (0.03–0.08) 0.06 (0.03–0.07) 0.82 0.22 0.78
9 (0.07–0.12) 0.10 (0.07–0.12) 0.79 0.20 0.039*
6 (0.01–0.10) 0.05 (0.02–0.09) 0.04* 0.65 0.09
7 (0.03–0.11) 0.08 (0.07–0.13) 0.41 0.15 0.61
5 (0.03–0.10) 0.07 (0.03–0.10) 0.86 0.71 0.15
7 (0.04–0.14) 0.08 (0.05–0.09) 0.61 0.38 0.30
6(0.04–0.10) 0.05 (0.05–0.09) 0.49 0.30 0.005*
6 (0.05–0.09) 0.05 (0.04–0.10) 0.67 0.89 0.78
5 (0.03–0.07) 0.03 (0.02–0.05) 0.12 0.30 0.17
7 (0.45–0.68) 0.59 (0.50–0.68) 0.79 0.27 0.57
7 (0.04–0.09) 0.04 (0.02–0.05) 0.74 0.04* 0.37
6 (0.05–0.07) 0.05 (0.04–0.07) 0.79 0.06 0.99
7 (0.04–0.09) 0.07 (0.05–0.10) 0.49 0.42 0.35
6 (0.28–0.45) 0.28 (0.22–0.32) 0.27 0.80 0.03*
7 (0.03–0.11) 0.05 (0.03–0.11) 0.86 0.38 0.48
4 (0.53–0.79) 0.73 (0.61–0.83) 0.24 0.76 0.92
2 (0.02–0.03) 0.02 (0.02–0.03) 0.95 0.84 0.43
4 (0.21–0.28) 0.22 (0.17–0.30) 0.31 0.97 0.12
5%.
Table 3 Baseline and End of Study Amino Acids in Controls and Cases
Baseline p+ End of the Study p+ A vs C{ B vs D{
Control (A) n = 15 Cases (B) n = 17 Control (C) n = 15 Case (D) n = 17
Alanine 213.00 (190.27 – 282.78) 238.00 (202.03 – 259.95) 0.59 240.00 (185.52 – 271.17) 208.00 (198.01 – 234.00) 0.59 0.84 0.09
Arginine 46.90 (40.51 – 62.78) 46.70 (38.55 – 52.69) 0.50 51.50 (32.61 – 68.11) 49.60 (37.35 – 59.99) 0.80 0.84 0.37
Citrulline 18.10 (14.95 – 20.41) 15.40 (14.20 – 15.99) 0.15 16.00 (12.96 – 18.42) 14.30 (12.61 – 17.18) 0.38 0.07 0.27
Glycine 200.00 (188.53 – 243.23) 224 (184.30 281.66) 0.42 205.00 (184.78 – 224.29) 208.00 (298.03 – 245.96) 0.34 0.89 0.40
Leucine 101.00 (84.59 – 108.20) 95.50 (85.85 - 101.97) 0.53 96.80 (89.02 – 111.67) 95.60 (91.83 – 104.93) 0.74 0.63 0.78
Methionine 42.90 (36.81 – 45.96) 40.10 (36.15 – 44.36) 0.50 44.00 (34.53 – 48.14) 40.20 (30.41 – 44.89) 0.23 0.76 0.54
Ornithine 74.20 (66.33 – 81.85) 79.40 (75.70 – 84.46) 0.28 69.20 (60.00 – 72.21) 66.00 (59.23 – 70.15) 0.40 0.21 0.003*
Phenylalanine 51.80 (44.61 – 53.71) 44.60 (43.20 – 49.09) 0.21 44.40 (40.06 – 49.91) 44.60 (42.90 – 47.67) 0.80 0.18 0.76
Tyrosine 49.80 (44.87 – 62.62) 45.50 (41.90 – 50.58) 0.26 45.90 (39.97 – 51.14) 41.50 (37.60 – 44.97) 0.05 0.16 0.05*
Valine 123.00 (97.69 – 153.35) 115.00 (101.09 – 142.67) 0.71 121.00 (102.11 – 141.35) 111.00 (98.99 – 124.87) 0.27 0.56 0.30
^ All values are in μmol/l. Results are reported in Median and 95% Confidence Interval.
+p Values were calculated by Mann–Whitney Test.
{p Values were calculated by Wilcoxon Rank Test.
* Significant Result p < 0.05.
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[95% CI 0.10 to 0.15] vs. 0.19 [95% CI 0.15 to 0.24]),
p = 0.05. The comparison between groups at the end of
the program showed a significant increase in medium-
chain AC C10 (0.06 [95% CI 0.04 to 0.15] vs. 0.11 [95%
CI 0.08 to 0.15]) in the case group only. See Table 2.
Amino acids
There was no difference found when the levels of amino
acids between the groups at the beginning of the AE
program were compared (Table 3). At the end of the ex-
ercise program a decrease in the levels of tyrosine and
ornithine in the group of cases with respect to baseline
was observed. In the control group there was no signifi-
cant change when compared with their baseline. Finally,
when comparing the final values between the groups
there was only a significant decrease in tyrosine levels in
the group of cases.
Discussion
Our study showed that a 10-week AE program in a young
population of obese women without DM significantly
decreased levels of long-chain AC (C18 and C14), only in
the case group, with a non-significant difference on
plasma free fatty acids during the study period. Although
there are many aspects that are still needed to be identi-
fied between the link of lipotoxicity and insulin resistance,
it is well known that an increase in intracellular lipid levels
leads to a decrease in insulin action [8,16,31]. If this is sec-
ondary to an excess of plasma free fatty acids and/or a de-
crease in their beta-oxidation is unclear [32]. This last
defect in patients with type 2 DM and obesity has been
shown to persist in the fasting state and is not removed
after an insulin stimulus with a euglycemic clamp [33,34].
This disorder, also known as metabolic inflexibility, has
been attributed to inhibition of CPT1 by malonyl-CoAleading to an inability to transport long-chain AC into the
mitochondrial matrix and thus the dysfunction in beta-
oxidation [21]. In our study, the identification of similar
levels of free fatty acids at baseline as well as at the end of
the intervention, suggests that beta-oxidation was
improved, being partially reversed, likely due to an in-
crease in CPT1 function, since a decrease in long-chain
AC (C14 and C18) occurred only in the case group as a
result of the AE program. This conclusion is strengthened
by the fact that pairs of long chain ACs (C14 and C18)
were those that were modified; the ACs pairs of up to 20
carbons accumulate in response to deterioration in beta-
oxidation of fatty acids in contrast with the accumulation
of odd ACs that result from the catabolism of amino acids,
except for C4, which is derived from both processes [22].
It is important to point out that the baseline AC pattern
was similar in both groups and agrees with that reported
previously [22].
When interpreting the mechanism of decline in long-
chain AC in the group of cases at the end of the study, it
is necessary to analyze the influence of a change in cal-
oric intake and a resulting decrease in body weight. The
influence of these on beta-oxidation has also been an
area of controversy [35,36]. In our study, both groups of
participants were carefully instructed not to alter their
caloric intake throughout the 10-week study. Conse-
quently, any changes in body weight should be a conse-
quence of the exercise program. Only the case group
showed a significant weight loss at the end of the exer-
cise program, which should be attributed to their better
adherence and intensity to the AE program. In accord-
ance with this concept is the fact that free fatty acid
levels remained unchanged in both groups during the
study. The favorable change in body weight and anthro-
pometry only due to weight loss without exercise should
not be regarded as the critical mechanism of metabolic
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group of 25 obese subjects without diabetes, found that
restoration of metabolic flexibility may be obtained by a
moderate weight loss as a consequence of an AE pro-
gram but not when compared to an equivalent weight
loss obtained from a program based solely on calorie re-
striction [34]. Consistent with this, in our study, only the
case group had a decrease in long-chain AC as a result
of improved beta-oxidation. A critical factor that
strengths the AE program in the case group, was that all
the anthropometric and metabolic variables where modi-
fied according to what is already well known [37-39]. As
well, amino acids, ornithine and tyrosine decreased as
previously described by AE [40].
Another important finding in our study was that in the
case group medium-chain AC C8 and C5 increased at
the end of the exercise program. Unlike long-chain AC,
medium chain AC did not depend on CPT1 for transfer
to the mitochondrial matrix. This would reinforce the
theory that improvement in beta-oxidation occurs mainly
as a result of an increase in CPT1 activity. Recent studies
agree with this finding, suggesting that intermediate pro-
ducts such as beta-oxidation of medium-chain AC accu-
mulate in patients with type 2 DM, reflecting that a more
complex beta-oxidation defect may be present; this ab-
normality was not reversed by the AE program our parti-
cipants underwent [31,35,41]. It could be that a more
intense AE program, with a greater length of time, in an
older population and with insulin resistance could im-
prove this defect in beta-oxidation in subjects who are
obese or have diabetes.
If the mitochondrial capacity of beta-oxidation is a
permanent or reversible defect is a matter of contro-
versy. Recent studies have found that mitochondrial
beta-oxidation is reduced in patients with type 2 DM
and that this abnormality is reversible [42,43]. In a group
of 10 patients with obesity and type 2 DM, Toledo et al.
(2007), in skeletal muscle biopsies, showed an improve-
ment in beta-oxidation after a moderate 16-week AE
program. In another study in 21 obese subjects undergo-
ing a 16-week AE program, muscle biopsies at the end
of the study identified an increased number of mito-
chondria and an increased amount of lipid droplets con-
sistent with the beneficial metabolic effects. Our results
show that a controlled 10-week AE program was able to
improve, in the case group, beta-oxidation.
Conclusions
A 10-week AE program led to well known anthropomet-
ric and biochemical modifications in a young group of
obese women without DM, improved beta-oxidation by
decreasing long-chain ACs probably due to an increase
in CPT1 function, being this a consequence of the phys-
ical activity and the weight loss that occurred as a directresult of the AE program. These findings warrant
longer-term studies to analyze their effects on long and
medium-chain AC and the permanence of these modifi-
cations after stopping exercise. So far our results suggest
that a long term AE program might likely improve lipo-
toxicity and, consequently, insulin action and pancreatic
beta cell functional reserve.Abbreviations
DM: Diabetes mellitus; ACs: Acylcarnitines; AE: Aerobic exercise;
CPT1: Carnitine palmitoyl transferase-1; BMI: Body mass index; HRR: Heart rate
reserve; MS/MS: Tandem mass spectrometry.
Competing interests
The authors declare they have no competing interests.
Acknowledgements
We wish to thank Sergio Lozano-Rodríguez, for his critical reading of the
manuscript.
Author details
1Endocrinology Division, Internal Medicine Department, “Dr. José E.
González”, University Hospital and Medical School of the Universidad
Autónoma de Nuevo León, Ave. Madero y Ave. Gonzalitos s/n, Colonia Mitras
Centro, Monterrey, Nuevo León 64460, Mexico. 2Genetics Department,
Medical School of the Universidad Autónoma de Nuevo León, Ave. Madero y
Dr. Eduardo Aguirre Pequeño s/n, Colonia Mitras Centro, Monterrey, Nuevo
León 64460, Mexico. 3Cardiovascular Exercise Laboratory, Nursing School of
the Benemérita Universidad Autónoma de Puebla, 4 sur 104, Centro
Histórico, Puebla 72000, Mexico. 4Investigation Department of the Hospital
General de Mexico, O.D, Dr. Balmis No.148, Col. Doctores, Delegación,
Cuauhtémoc 06726, Mexico. 5Investigation Department, Nursing School,
Universidad Autónoma de Nuevo León, Av. Gonzalitos 1500 Norte, Colonia
Mitras Centro, Monterrey, Nuevo León 64460, Mexico. 6Servicio de
Endocrinología, Hospital Universitario Dr. José E. Gonzalez, Ave. Madero y
Gonzalitos s/n, Colonia Mitras Centro, Monterrey, Nuevo León 64460, Mexico.
Author’s contributions
RRG, FJLG served as the principal investigators and contributed to study
design, data collection, and manuscript preparation. LEMG, ELO, JCLA
contributed to study design, data collection and manuscript preparation.
MRTS contributed to de acylcarnitine measures, participated in statistical
analysis and manuscript preparation. JGGG contributed to data collection
and manuscript preparation, LGMA participated in statistical analysis and
manuscript preparation. BSG, JZVP contributed to the coordination and
helped draft the manuscript. All authors read and approved the final
manuscript.
Received: 2 February 2012 Accepted: 10 May 2012
Published: 10 May 2012
References
1. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W: Annual medical spending
attributable to obesity: payer- and service-specific estimates. Health Aff
(Millwood) 2009, 28:822–831.
2. Hogan P, Dall T, Nikolov P: Economic costs of diabetes in the U.S. in 2002.
Diabetes Care 2003, 26:917–932.
3. World Health Organization: World Health Organization Consultation on
Obesity. Geneva: WHO; 2000.
4. Boyle J, Honeycutt A, Narayan K, Hoerger T, Geiss L, Chen H, Thompson T:
Projection of diabetes burden through 2050: impact of changing
demography and disease prevalence in the U.S. Diabetes Care 2001,
24:1936–1940.
5. Mokdad A, Bowman B, Ford E, Vinicor F, Marks J, Koplan J: The continuing
epidemics of obesity and diabetes in the United States. J Am Med Assoc
2001, 286:1195–1200.
6. Dommarco JR, Cuevas Nasu L, Shamah Levy T, Villalpando Hernández S,
Avila Arcos MA, Jiménez Aguilar A: Nutrición. In Encuesta Nacional de
Rodríguez-Gutiérrez et al. Journal of the International Society of Sports Nutrition 2012, 9:22 Page 8 of 8
http://www.jissn.com/content/9/1/22Salud y Nutrición. Cuernavaca, Mexico: Instituto Nacional de Salud Pública;
2006.
7. Villalpando Hernandez S, Cruz V, Rojas R, Shamah Levy T, Ávila MA, Berenice
Gaona B, Rebollar Hernández L: Prevalence and distribution of type 2
diabetes mellitus in Mexican adult population. A probabilistic survey.
Salud Pública de México 2010, 52:19–26.
8. DeFronzo RA: Lilly Lecture: The triumvirate: cell, muscle, liver: a collusion
responsible for NIDDM. Diabetes 1988, 37:667–687.
9. Reaven GM: Role of insulin resistance in human disease. Diabetes 1988,
37:1595–1607.
10. Abdul-Ghani M, DeFronzo RA: Inhibition of renal glucose reabsorption: a
novel strategy for achieving glucose control in type 2 diabetes mellitus.
Endocr Pract 2008, 14:782–790.
11. Boden G, Shulman GI: Free fatty acids in obesity and type 2 diabetes:
defining their role in the development of insulin resistance and β-cell
dysfunction. Eur J Clin Invest 2002, 32(Suppl 3):14–23.
12. DeFronzo RA: From the triumvirate to the ominous octet: A new
paradigm for the treatment of type 2 Diabetes Mellitus. Diabetes 2009,
58:773–795.
13. Matsuda M, DeFronzo RA, Glass L, Consoli A, Giordano M, Bressler P, Del
Prato S: Glucagon dose response curve for hepatic glucose production
and glucose disposal in type 2 diabetic patients and normal individuals.
Metabolism 2002, 51:1111–1119.
14. Matsuda M, Liu Y, Mahankali S, Pu Y, Mahankali A, Wang J, DeFronzo RA,
Fox PT, Gao JH: Altered hypothalamic function in response to glucose
ingestion in obese humans. Diabetes 1999, 48:1801–1806.
15. Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB: Documentation of
hyperglucagonemia throughout the day in nonobese and obese
patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol
Metab 1987, 64:106–110.
16. Unger RH: Lipotoxic diseases. Annu Rev Med 2002, 53:319–336.
17. Longo N, San Filippo CA, Pasquali M: Disorders of carnitine trasport and
carnitine cycle. Am J Med Genet C Semin Med Genet 2006, 142:77–85.
18. Randle PJ, Garland PB, Hales CN, Newsholme EA: The glucose fatty-acid
cycle: its role in insulin sensitivity and the metabolic disturbances of
diabetes mellitus. Lancet 1963, 1:785–789.
19. Kelley DE, He J, Menshikova EV, Ritov VB: Dysfunction of mitochondria in
human skeletal muscle in type 2 diabetes. Diabetes 2002, 51:2944–2950.
20. Koves TR, Ussher JR, Noland RC, Sientz D, Mosedale M, Ilkayeva O, Bain J,
Stevens R, Dyck JR, Newgard CB, Lopaschuk GD, Muoio DM: Mitochondrial
overload and incomplete fatty acid oxidation contribute to skeletal
muscle insulin resistance. Cell Metab 2008, 7:45–56.
21. McGarry JD, Brown NF: The mitochondrial carnitine palmitoyltransferase
system. From concept to molecular analysis. Eur J Biochem 1997,
244:1–14.
22. Mihalik SJ, Goodpaster BH, Kelley DE, Chace DH, Vockley J, Toledo FG,
Delany JP: Levels of plasma acylcarnitines in obesity and type 2 diabetes
and identification of a marker of glucolipotoxicity. Obesity (Silver Spring)
2010, 18:1695–1700.
23. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA:
Thiazolidinediones improve beta-cell function in type 2 diabetic
patients. Am J Physiol Endocrinol Metab 2007, 292:871–883.
24. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferranini E, Cusi K,
Mandarino L, DeFronzo RA: Improved glycemic control and enhanced
insulin sensitivity in liver and muscle in type 2 diabetic subjects treated
with pioglitazone. Diabetes Care 2001, 24:710–719.
25. Hiatt WR, Regensteiner JG, Wolfel EE, Ruff L, Brass EP: Carnitine and
acylcarnitine metabolism during exercise in Humans. J Clin Invest 1989,
84:1167–1173.
26. American College of Sports Medicine: ACSM’s Guidelines for exercise testing
and prescription. 8th edition. New York: Lippinkott Williams & Wilkins; 2010.
27. Noble BJ, Borg GA, Jacobs I, Ceci R, Kaiser P: A category-ratio perceived
exertion scale: relationship to blood and muscle lactates and heart rate.
Med Sci Sports Exerc 1983, 5:523–528.
28. National Institutes of Health: Clinical guidelines on the identification,
evaluation and treatment of overweight and obesity in adults: the
evidence report. Obes Res 1998, 2(Suppl 6):461–462.
29. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC:
Homeostasis model assessment: insulin resistance and beta-cell function
from fasting plasma glucose and insulin concentrations in man.
Diabetologia 1985, 28:412–419.30. Hanley AJ, Williams K, Stern MP, Haffner SM: Homeostasis model
assessment of insulin resistance in relation to the incidence of
cardiovascular disease: the San Antonio Heart Study. Diabetes Care 2002,
25:1177–1184.
31. Adams SH, Hoppel CL, Lok KH, Zhao L, Wong SW, Minkler PE, Hwang DH,
Newman JW, Garvey WT: Plasma acylcarnitine profiles suggest
incomplete long-chain fatty acid β-oxidation and altered tricarboxylic
acid cycle activity in type 2 diabetic African-American women. J Nutr
2009, 139:1073–1081.
32. Kelley DE: Skeletal muscle fat oxidation: timing and flexibility are
everything. J Clin Invest 2005, 115:1699–1702.
33. Kelley DE, Goodpaster BH, Wing RR, Simoneau JA: Skeletal muscle fatty
acid metabolism in association with insulin resistance, obesity and
weight loss. Am J Physiol 1999, 277:1130–1141.
34. Goodpaster BH, Katsiaras A, Kelley DE: Enhanced fat oxidation through
physical activity is associated with improvements in insulin sensitivity in
obesity. Diabetes 2003, 52:2191–2197.
35. Chitwood LF, Brown SP, Lundy MJ, Dupper MA: Metabolic propensity
toward obesity in black vs white females: responses during rest, exercise
and recovery. Int J Obes Relat Metab Disord 1996, 20:455–462.
36. Franck N, Gummesson A, Jernas M, Glad C, Svensson PA, Guillot G, Rudemo
M, Nystörm FH, Carlsson LM, Olsson B: Identification of adipocyte genes
regulated by caloric intake. J Clin Endocrinol Metab 2011, 96:413–418.
37. Kraemer RR, Chu H, Castracane VD: Leptin and exercise. Exp Biol Med 2002,
227:701–708.
38. Kriketos AD, Gan SK, Poynten AM, Furler SM, Chisholm DJ, Campbell MB:
Exercise increases adiponectin levels and insulin sensitivity in humans.
Diabetes Care 2004, 27:629–630.
39. Ross R, Dagnone D, Jones PJH, Smith H, Paddags A, Hudson R, Janssen I:
Reduction in obesity and related comorbid conditions after diet-induced
weight loss or exercise-induced weight loss in men. Ann Intern Med 2000,
133:92–103.
40. Brodan V, Kuhn E, Pechar J, Tomkovfi D: Changes in free amino acids in
plasma of healthy subjects induced by physical exercise. Europ J appl
Physiol 1976, 35:69–77.
41. Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, Hagg AM,
Shah SH, Arlotto M, Slentz CA, Rochon J, Gallup D, Ilkayeva O, Wenner BR,
Yancy WS Jr, Eisenson H, Musante G, Surwit RS, Millington DS, Butler MD,
Svetkey LP: A branched-chain amino acid-related metabolic signature
that differentiates obese and lean humans and contributes to insulin
resistance. Cell Metab 2009, 9:311–326.
42. He J, Bret H, Goodpaster BH, Kelley DE: Effects of weight loss and physical
activity on muscle lipid content and droplet size. Obes Res 2004,
12:761–769.
43. Toledo GS, Menshikova EV, Ritov VB, Azuma K, Radikova Z, DeLany J, Kelley
DE: Effects of physical activity and weight loss on skeletal muscle
mitochondria and relationship with glucose control in type 2 diabetes.
Diabetes 2007, 56:2142–2147.
doi:10.1186/1550-2783-9-22
Cite this article as: Rodríguez-Gutiérrez et al.: Impact of an exercise
program on acylcarnitines in obesity: a prospective controlled study.
Journal of the International Society of Sports Nutrition 2012 9:22.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
